首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.
【24h】

Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.

机译:非清髓同种异体干细胞移植后,来自A 3-6 / 6 HLA匹配家庭成员的富含自然杀伤细胞的供体淋巴细胞输注。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Infusing natural killer (NK) cells following transplantation may allow less infections and relapse with little risk of acute graft-versus-host disease (aGVHD). We delivered 51 total NK cell-enriched donor lymphocyte infusions (DLIs) to 30 patients following a 3-6/6 HLA matched T cell-depleted nonmyeloablative allogeneic transplant. The primary endpoint of this study was feasibility and safety. Eight weeks following transplantation, donor NK cell-enriched DLIs were processed using a CD56(+) selecting column with up to 3 fresh infusions allowed. Toxicity, relapse, and survival were monitored. T cell phenotype, NK cell functional recovery, and KIR typing were assessed for association with outcomes. Fourteen matched and 16 mismatched transplanted patients received a total of 51 NK cell-enriched DLIs. Selection resulted in 96% (standard deviation [SD] 8%) purity and 83% (SD 21%) yield in the matched setting and 97% (SD 3%) purity and 77% (SD 24%) yield in the mismatched setting. The median number of CD3(-) CD56(+) NK cells infused was 10.6 (SD 7.91) x 10(6) cells/kg and 9.21 (SD 5.6) x 10(6) cells/kg, respectively. The median number of contaminating CD3(+)CD56(-) T cells infused was .53 (1.1) x 10(6) and .27 (.78) x 10(6) in the matched and mismatched setting, respectively. Only 1 patient each in the matched (n = 14) or mismatched (n = 16) setting experienced severe aGVHD with little other toxicity attributable to the infusions. Long-term responders with multiple NK cell-enriched infusions and improved T cell phenotypic recovery had improved duration of responses (p = .0045) and overall survival (OS) (P = .0058). A 1-step, high-yield process is feasible, and results in high doses of NK cells infused with little toxicity. NK cell-enriched DLIs result in improved immune recovery and outcomes for some. Future studies must assess whether the improved outcomes are the direct result of the high doses and improved NK cell function or other aspects of immune recovery.
机译:移植后注入自然杀伤(NK)细胞可以减少感染和复发,并且急性移植物抗宿主病(aGVHD)的风险很小。在3-6 / 6 HLA匹配的T细胞贫化的非清髓同种异体移植后,我们向30名患者提供了51例NK细胞富集的供体淋巴细胞输注液(DLI)。这项研究的主要终点是可行性和安全性。移植后八周,使用CD56(+)选择柱处理供体NK细胞富集的DLI,最多允许3次新鲜输注。监测毒性,复发和生存。评估T细胞表型,NK细胞功能恢复和KIR分型与预后的关系。 14位匹配的和16位错配的移植患者总共接受了51个NK细胞富集的DLI。通过选择,在匹配的设置中可获得96%(标准偏差[SD] 8%)纯度和83%(SD 21%)的产率,在不匹配的设置中可获得97%(SD 3%)的纯度和77%(SD 24%)的产率。注入的CD3(-)CD56(+)NK细胞的中位数分别为10.6(SD 7.91)x 10(6)细胞/ kg和9.21(SD 5.6)x 10(6)细胞/ kg。在匹配和不匹配设置下,注入的污染性CD3(+)CD56(-)T细胞的中位数分别为0.53(1.1)x 10(6)和.27(.78)x 10(6)。在匹配(n = 14)或不匹配(n = 16)的情况下,只有1名患者经历了严重的aGVHD,几乎没有其他可归因于输注的毒性。具有多次NK细胞富集输注和改善的T细胞表型恢复的长期应答者,应答持续时间(p = .0045)和总生存期(OS)(P = .0058)有所改善。第一步,高产量的方法是可行的,并导致注入高剂量的NK细胞而几乎没有毒性。富含NK细胞的DLI可以改善某些人的免疫恢复和结果。未来的研究必须评估改善的结果是否是高剂量和改善的NK细胞功能或免疫恢复其他方面的直接结果。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号